tiprankstipranks
Quince Therapeutics (QNCX)
NASDAQ:QNCX
US Market
QNCX
Quince Therapeutics
RESEARCH TOOLSreports
Want to see QNCX full AI Analyst Report?

Quince Therapeutics (QNCX) Stock Forecast & Price Target

1,040 Followers
See the Price Targets and Ratings of:

QNCX Analyst Ratings

Strong Buy
3Ratings
Strong Buy
3 Buy
0 Hold
0 Sell
Based on 3 analysts giving stock ratings to
Quince
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

QNCX Stock 12 Month Forecast

Average Price Target

$4.33
▲(216.30% Upside)
Based on 3 Wall Street analysts offering 12 month price targets for Quince Therapeutics in the last 3 months. The average price target is $4.33 with a high forecast of $5.00 and a low forecast of $4.00. The average price target represents a 216.30% change from the last price of $1.37.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","170":"$170","337":"$337","504":"$504","671":"$671"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$5.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.333333333333333,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$4.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,170,337,504,671],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.75,15.846153846153847,14.942307692307692,14.038461538461538,13.134615384615385,12.23076923076923,11.326923076923077,10.423076923076923,9.51923076923077,8.615384615384615,7.711538461538462,6.807692307692308,5.903846153846153,{"y":5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.75,15.794871794871796,14.83974358974359,13.884615384615385,12.929487179487179,11.974358974358974,11.01923076923077,10.064102564102564,9.108974358974358,8.153846153846153,7.198717948717949,6.243589743589743,5.288461538461538,{"y":4.333333333333333,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.75,15.76923076923077,14.788461538461538,13.807692307692308,12.826923076923077,11.846153846153847,10.865384615384617,9.884615384615385,8.903846153846153,7.923076923076923,6.942307692307693,5.961538461538462,4.980769230769232,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":304,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":336,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":320,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":324,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":330,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":634,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":670,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":19.76,"date":1772323200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":20.46,"date":1775001600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":26.6,"date":1777593600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":22.2,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.75,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$5.00Average Price Target$4.33Lowest Price Target$4.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
LifeSci Capital Analyst forecast on QNCX
Sam Slutsky
LifeSci Capital
LifeSci Capital
$5
Buy
264.96%
Upside
Initiated
06/29/26
Analyst Reiterates Buy on Quince Therapeutics, Citing Differentiated LAM-001 Mechanism, Underserved PH-ILD Market, and Solid Cash Runway
Cantor Fitzgerald Analyst forecast on QNCX
Olivia Brayer
Cantor Fitzgerald
Cantor Fitzgerald
$4
Buy
191.97%
Upside
Initiated
06/25/26
Quince Therapeutics initiated with an Overweight at Cantor FitzgeraldQuince Therapeutics initiated with an Overweight at Cantor Fitzgerald
Leerink Partners Analyst forecast on QNCX
Joseph Schwartz
Leerink Partners
Leerink Partners
$4
Buy
191.97%
Upside
Initiated
06/24/26
Quince Therapeutics initiated with an Outperform at LeerinkQuince Therapeutics initiated with an Outperform at Leerink
Maxim Group Analyst forecast on QNCX
Jason McCarthy
Maxim Group
Maxim Group
―
Hold
―
Downgraded
02/02/26
Quince Therapeutics downgraded to Hold from Buy at MaximQuince Therapeutics downgraded to Hold from Buy at Maxim
Lucid Capital Analyst forecast on QNCX
Elemer Piros
Lucid Capital
Lucid Capital
―
Sell
―
Downgraded
01/30/26
Quince Therapeutics downgraded to Sell from Buy at Lucid Capital (earlier)Quince Therapeutics downgraded to Sell from Buy at Lucid Capital (earlier)
D. Boral Capital Analyst forecast on QNCX
Jason Kolbert
D. Boral Capital
D. Boral Capital
―
Hold
―
Downgraded
01/30/26
Quince Therapeutics downgraded to Hold from Buy at D. Boral CapitalQuince Therapeutics downgraded to Hold from Buy at D. Boral Capital
Citizens JMP Analyst forecast on QNCX
Jonathan Wolleben
Citizens JMP
Citizens JMP
―
Hold
―
Downgraded
01/29/26
Quince Therapeutics downgraded to Market Perform from Outperform at CitizensQuince Therapeutics downgraded to Market Perform from Outperform at Citizens
Oppenheimer Analyst forecast on QNCX
Leland Gershell
Oppenheimer
Oppenheimer
$100
Buy
7199.27%
Upside
Reiterated
11/14/25
Oppenheimer Sticks to Its Buy Rating for Quince Therapeutics (QNCX)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
LifeSci Capital Analyst forecast on QNCX
Sam Slutsky
LifeSci Capital
LifeSci Capital
$5
Buy
264.96%
Upside
Initiated
06/29/26
Analyst Reiterates Buy on Quince Therapeutics, Citing Differentiated LAM-001 Mechanism, Underserved PH-ILD Market, and Solid Cash Runway
Cantor Fitzgerald Analyst forecast on QNCX
Olivia Brayer
Cantor Fitzgerald
Cantor Fitzgerald
$4
Buy
191.97%
Upside
Initiated
06/25/26
Quince Therapeutics initiated with an Overweight at Cantor FitzgeraldQuince Therapeutics initiated with an Overweight at Cantor Fitzgerald
Leerink Partners Analyst forecast on QNCX
Joseph Schwartz
Leerink Partners
Leerink Partners
$4
Buy
191.97%
Upside
Initiated
06/24/26
Quince Therapeutics initiated with an Outperform at LeerinkQuince Therapeutics initiated with an Outperform at Leerink
Maxim Group Analyst forecast on QNCX
Jason McCarthy
Maxim Group
Maxim Group
―
Hold
―
Downgraded
02/02/26
Quince Therapeutics downgraded to Hold from Buy at MaximQuince Therapeutics downgraded to Hold from Buy at Maxim
Lucid Capital Analyst forecast on QNCX
Elemer Piros
Lucid Capital
Lucid Capital
―
Sell
―
Downgraded
01/30/26
Quince Therapeutics downgraded to Sell from Buy at Lucid Capital (earlier)Quince Therapeutics downgraded to Sell from Buy at Lucid Capital (earlier)
D. Boral Capital Analyst forecast on QNCX
Jason Kolbert
D. Boral Capital
D. Boral Capital
―
Hold
―
Downgraded
01/30/26
Quince Therapeutics downgraded to Hold from Buy at D. Boral CapitalQuince Therapeutics downgraded to Hold from Buy at D. Boral Capital
Citizens JMP Analyst forecast on QNCX
Jonathan Wolleben
Citizens JMP
Citizens JMP
―
Hold
―
Downgraded
01/29/26
Quince Therapeutics downgraded to Market Perform from Outperform at CitizensQuince Therapeutics downgraded to Market Perform from Outperform at Citizens
Oppenheimer Analyst forecast on QNCX
Leland Gershell
Oppenheimer
Oppenheimer
$100
Buy
7199.27%
Upside
Reiterated
11/14/25
Oppenheimer Sticks to Its Buy Rating for Quince Therapeutics (QNCX)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Quince Therapeutics

3 Months
Elemer PirosLucid Capital
Success Rate
2/2 ratings generated profit
100%
Average Return
+18.65%
Copying Elemer Piros's trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +18.65% per trade.
1 Year
Elemer PirosLucid Capital
Success Rate
1/2 ratings generated profit
50%
Average Return
-21.80%
Copying Elemer Piros's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -21.80% per trade.
2 Years
Elemer PirosLucid Capital
Success Rate
1/2 ratings generated profit
50%
Average Return
-21.80%
Copying Elemer Piros's trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of -21.80% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

QNCX Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
0
0
0
0
0
Buy
0
0
0
3
3
Hold
3
1
0
0
0
Sell
1
0
0
0
0
Strong Sell
0
0
0
0
0
total
4
1
0
3
3
In the current month, QNCX has received 3 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. QNCX average Analyst price target in the past 3 months is 4.33.
Each month's total comprises the sum of three months' worth of ratings.

QNCX Financial Forecast

QNCX Earnings Forecast

Next quarter’s earnings estimate for QNCX is -$9.40 with a range of -$18.00 to -$0.80. The previous quarter’s EPS was $3.91. QNCX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year QNCX has Performed in-line its overall industry.
Next quarter’s earnings estimate for QNCX is -$9.40 with a range of -$18.00 to -$0.80. The previous quarter’s EPS was $3.91. QNCX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year QNCX has Performed in-line its overall industry.
No data currently available

QNCX Sales Forecast

Next quarter’s sales forecast for QNCX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. QNCX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year QNCX has Performed in-line its overall industry.
Next quarter’s sales forecast for QNCX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. QNCX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year QNCX has Performed in-line its overall industry.

QNCX Stock Forecast FAQ

What is QNCX’s average 12-month price target, according to analysts?
Based on analyst ratings, Quince Therapeutics’s 12-month average price target is 4.33.
    What is QNCX’s upside potential, based on the analysts’ average price target?
    Quince Therapeutics has 216.30% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is QNCX a Buy, Sell or Hold?
          Quince Therapeutics has a consensus rating of Strong Buy which is based on 3 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Quince Therapeutics’s price target?
            The average price target for Quince Therapeutics is 4.33. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $5.00 ,the lowest forecast is $4.00. The average price target represents 216.30% Increase from the current price of $1.37.
              What do analysts say about Quince Therapeutics?
              Quince Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.
                How can I buy shares of QNCX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.